Bulk RNA-seq of MDA-MB-231 cells under dasatinib treatment
Triple-negative breast cancer (TNBC) is characterized by high metastatic potential and poor prognosis, underscoring the urgent need for effective therapeutic strategies.  Dasatinib emerged as a promising anti-metastatic agent in TNBC.To elucidate the molecular mechanisms by which dasatinib inhibits breast cancer progression, we conducted bulk RNA sequencing (RNA-seq) on MDA-MB-231 cells treated for 6, 12, 24, and 48 hours. Overall design: Transcriptomic analysis of MDA-MB-231 cells following dasatinib 0,6,12,24,48 hours-treatment.